- Home
- Technology
- Services
- mRNA Display-based Antibody Discovery
- mRNA Display-based Peptide Discovery
- mRNA Display-based Protein Discovery
- Applications
- About
Peptides are widely used in gene/drug delivery and disease targeting therapy, but natural peptides are easy to be hydrolyzed by protease in vivo with short half-life. Many studies are devoted to improving the delivery and therapeutic stability of peptides. CD BioSciences has accumulated rich experience in peptide research. Using the peptide discovery platform based on mRNA display technology, it can screen highly stable peptide ligands for target molecules for drug delivery and therapeutic research.
Peptides, as new therapeutic molecules and excellent drug carriers, have been widely used in cancer therapy, tumor imaging, immunotherapy and other fields in recent years. As gene/drug carriers, peptides have the advantages of low toxicity, low immunogenicity, high tissue permeability and easy synthesis and modification. However, peptide is easy to be degraded by a variety of proteases, and has a high clearance rate of blood and kidney, leading to poor stability in vivo, and there are many limitations in practical application. The main reason why peptides are unstable is that the main chain is prone to deamidation reaction, especially the amide group on the molecular surface is easy to be recognized and hydrolyzed by protease. The amino acid residues on the side chain are also prone to conformational changes, such as α- Spiral dissociation and salt bridge fracture.
Common methods to improve the stability of peptides involved in biological circulation include changing single or multiple amino acids in peptides, such as deleting and replacing amino acids at sites easily recognized by protease; Modification of both ends of peptide, such as C-end modification (amidation, sulfation, etc.), N-end modification (acetylation, fatty acidification, etc.); Macromolecule modification can also be carried out, such as biological modification, PEG modification and peptide cyclization. At present, in vitro display technology is used to screen these peptides designed and modified by special sequences. In addition, the selective pressure of additional protease and other degrading enzymes will be applied to obtain the target peptide molecules with greatly improved in vivo stability and half-life. These peptides are expected to become new oral targeted drugs for the treatment of diseases.
Fig. 1 Selection for macrocyclic drug candidates. (Newton, et al., 2020)
Based on mRNA display technology, CD BioSciences can provide customers around the world with screening and development services for highly stable peptides, and help customers around the world with basic research and drug discovery. Our service process of high stability peptide screening:
High-throughput Screening
Fast Turnaround Time
Customized Service
Achieve High Stability
CD BioSciences has many years of project development experience in peptide discovery. Based on the mRNA display technology platform, it can provide customers with screening services for various peptides. If you are interested in our services, please contact us for more details.
Reference
